NCT03598998View on ClinicalTrials.gov

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

May 3, 2023

Study Completion Date

February 26, 2026

Conditions
Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Monomorphic Epitheliotropic Intestinal T-cell LymphomaRecurrent Mycosis FungoidesRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSubcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Pralatrexate

Given IV

Trial Locations (3)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

68198

University of Nebraska Medical Center, Omaha

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER